AxoGen Inc. (NASDAQ:AXGN) – Equities research analysts at Wedbush dropped their FY2018 EPS estimates for AxoGen in a report issued on Monday. Wedbush analyst Levy. T now expects that the firm will earn $0.11 per share for the year, down from their prior forecast of $0.12. Wedbush has a “Outperform” rating and a $10.00 price target on the stock. Wedbush also issued estimates for AxoGen’s FY2019 earnings at $0.52 EPS.
AxoGen (NASDAQ:AXGN) traded up 1.71% on Wednesday, hitting $8.90. 73,220 shares of the company’s stock were exchanged. The company’s 50-day moving average price is $8.73 and its 200-day moving average price is $7.06. AxoGen has a 12-month low of $4.08 and a 12-month high of $9.88. The company’s market cap is $268.17 million.
AxoGen (NASDAQ:AXGN) last posted its quarterly earnings results on Wednesday, August 3rd. The company reported ($0.09) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.12) by $0.03. AxoGen had a negative net margin of 37.90% and a negative return on equity of 193.60%.
Several large investors have recently added to or reduced their stakes in the stock. California State Teachers Retirement System bought a new stake in AxoGen during the second quarter worth about $348,000. Bank of New York Mellon Corp increased its stake in AxoGen by 196.8% in the second quarter. Bank of New York Mellon Corp now owns 80,580 shares of the company’s stock worth $555,000 after buying an additional 53,427 shares during the period. UBS Group AG increased its stake in AxoGen by 991.7% in the first quarter. UBS Group AG now owns 97,946 shares of the company’s stock worth $525,000 after buying an additional 88,974 shares during the period. Waddell & Reed Financial Inc. bought a new stake in AxoGen during the second quarter worth about $1,371,000. Finally, State Street Corp bought a new stake in AxoGen during the second quarter worth about $1,885,000. 57.87% of the stock is currently owned by institutional investors and hedge funds.
In related news, CEO Karen L. Zaderej purchased 10,000 shares of AxoGen stock in a transaction dated Friday, October 7th. The shares were acquired at an average cost of $7.50 per share, with a total value of $75,000.00. Following the purchase, the chief executive officer now owns 242,147 shares of the company’s stock, valued at $1,816,102.50. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Joseph M. Mandato sold 149,618 shares of the business’s stock in a transaction that occurred on Tuesday, August 9th. The shares were sold at an average price of $8.54, for a total transaction of $1,277,737.72. The disclosure for this sale can be found here. 9.33% of the stock is currently owned by insiders.
Receive News & Ratings for AxoGen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.